Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
INZY Stock Summary
Top 10 Correlated ETFs
INZY
In the News
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m.
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company's chief executive officer and chairman of the board, will participate at the following investor conferences:
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.
3 Penny Stocks To Buy According To Insiders In August 2023
Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains.
Inozyme Pharma to Present at the Jefferies Healthcare Conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET.
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company's senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.
Pivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme Pharma
Fintel reports that Pivotal bioVenture Partners Fund I has filed a 13D/A form with the SEC disclosing ownership of 3.21MM shares of Inozyme Pharma Inc (INZY).
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data
Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy.
Choosing Penny Stocks for Short Term Trading; 3 Tips
Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
INZY Financial details
INZY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.23 | -5.06 | -2.39 | -1.73 | -1.37 | |
Operating cash flow per share | -1.24 | -3.26 | -2.04 | -1.53 | -1.36 | |
Free cash flow per share | -1.25 | -3.31 | -2.06 | -1.54 | -1.37 | |
Cash per share | 3.11 | 25.33 | 4.75 | 3.39 | 3.64 | |
Book value per share | -2.19 | 14.33 | 4.64 | 3.14 | 2.71 | |
Tangible book value per share | -2.19 | 14.33 | 4.64 | 3.14 | 2.71 | |
Share holders equity per share | -2.19 | 14.33 | 4.64 | 3.14 | 2.71 | |
Interest debt per share | 0 | 0.09 | 0.14 | 0.14 | 0.95 | |
Market cap | 265.89M | 227.79M | 160.67M | 39.65M | 220.83M | |
Enterprise value | 234.29M | 69.18M | 140.72M | 13.51M | 232.84M | |
P/E ratio | -14.28 | -4.08 | -2.85 | -0.61 | -3.1 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -14.14 | -6.33 | -3.34 | -0.69 | -3.12 | |
PFCF ratio | -14.03 | -6.23 | -3.31 | -0.68 | -3.11 | |
P/B Ratio | -8 | 1.44 | 1.47 | 0.33 | 1.57 | |
PTB ratio | -8 | 1.44 | 1.47 | 0.33 | 1.57 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.31 | -1.21 | -2.51 | -0.2 | -3.13 | |
EV to operating cash flow | -12.46 | -1.92 | -2.92 | -0.23 | -3.29 | |
EV to free cash flow | -12.36 | -1.89 | -2.9 | -0.23 | -3.28 | |
Earnings yield | -0.07 | -0.25 | -0.35 | -1.65 | -0.32 | |
Free cash flow yield | -0.07 | -0.16 | -0.3 | -1.47 | -0.32 | |
Debt to equity | 0 | 0.01 | 0.03 | 0.06 | 0.33 | |
Debt to assets | 0 | 0.01 | 0.03 | 0.05 | 0.23 | |
Net debt to EBITDA | 1.53 | 2.78 | 0.36 | 0.38 | -0.16 | |
Current ratio | 14.67 | 15.14 | 9.92 | 8.93 | 13.36 | |
Interest coverage | 0 | 0 | 0 | 42.55 | -22.7 | |
Income quality | 0.95 | 0.64 | 0.85 | 0.86 | 0.99 | |
Dividend Yield | 0 | 0 | 0 | 0.1 | 0.18 | |
Payout ratio | 0 | 0 | 0 | -0.06 | -0.57 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.67 | -2.62 | -0.59 | -0.55 | -0.23 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 7.78 | 40.38 | 15.81 | 11.07 | 9.15 | |
ROIC | 0.59 | -0.35 | -0.49 | -0.52 | -0.4 | |
Return on tangible assets | -0.39 | -0.33 | -0.46 | -0.47 | -0.35 | |
Graham Net | -2.24 | 23.76 | 4.14 | 2.84 | 2.48 | |
Working capital | 44.22M | 141.01M | 103.71M | 116.68M | 181.56M | |
Tangible asset value | -33.22M | 158.1M | 109.27M | 118.39M | 140.48M | |
Net current asset value | -33.7M | 139.72M | 101.07M | 110.59M | 135.88M | |
Invested capital | 0 | 0.01 | 0.03 | 0.06 | 0.33 | |
Average receivables | 67.5K | 129.5K | 108.5K | 88.5K | 250K | |
Average payables | 942.5K | 1.99M | 2.73M | 2.47M | 1.86M | |
Average inventory | 0 | -6.18M | -6.21M | -88.5K | -57.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 3.96K | 5.16K | 830.62 | 788.92 | 328.89 | |
Days of inventory on hand | 0 | -20.78K | -21.51 | -35.66 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.09 | 0.07 | 0.44 | 0.46 | 1.11 | |
Inventory turnover | 0 | -0.02 | -16.97 | -10.23 | 0 | |
ROE | 0.56 | -0.35 | -0.52 | -0.55 | -0.51 | |
Capex per share | -0.01 | -0.05 | -0.02 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.46 | -0.37 | -0.35 | -0.29 | -0.35 | |
Operating cash flow per share | -0.38 | -0.41 | -0.35 | -0.33 | -0.3 | |
Free cash flow per share | -0.38 | -0.41 | -0.35 | -0.33 | -0.3 | |
Cash per share | 3.39 | 2.99 | 3.13 | 3.39 | 3.05 | |
Book value per share | 3.14 | 2.36 | 2.35 | 2.82 | 2.27 | |
Tangible book value per share | 3.14 | 2.36 | 2.35 | 2.82 | 2.27 | |
Share holders equity per share | 3.14 | 2.36 | 2.35 | 2.82 | 2.27 | |
Interest debt per share | 0.15 | 0.58 | 0.76 | 0.6 | 0.79 | |
Market cap | 39.65M | 250.52M | 249.87M | 238.39M | 263.13M | |
Enterprise value | 13.51M | 228.16M | 243.14M | 225.59M | 275.14M | |
P/E ratio | -0.56 | -3.86 | -4.01 | -3.58 | -3.05 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.75 | -14.1 | -16.07 | -12.63 | -14.23 | |
PFCF ratio | -2.74 | -13.96 | -16.06 | -12.63 | -14.15 | |
P/B Ratio | 0.33 | 2.42 | 2.37 | 1.49 | 1.87 | |
PTB ratio | 0.33 | 2.42 | 2.37 | 1.49 | 1.87 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.7 | -12.42 | -15.02 | -12.48 | -12.23 | |
EV to operating cash flow | -0.94 | -12.84 | -15.64 | -11.96 | -14.88 | |
EV to free cash flow | -0.94 | -12.71 | -15.63 | -11.95 | -14.8 | |
Earnings yield | -0.44 | -0.06 | -0.06 | -0.07 | -0.08 | |
Free cash flow yield | -0.36 | -0.07 | -0.06 | -0.08 | -0.07 | |
Debt to equity | 0.06 | 0.26 | 0.32 | 0.21 | 0.33 | |
Debt to assets | 0.05 | 0.19 | 0.23 | 0.17 | 0.23 | |
Net debt to EBITDA | 1.35 | 1.22 | 0.42 | 0.71 | -0.53 | |
Current ratio | 8.93 | 10.66 | 11.89 | 16.36 | 13.36 | |
Interest coverage | 19.75 | 15.67 | 0 | 0 | -6.84 | |
Income quality | 0.78 | 1.02 | 1 | 1.13 | 0.86 | |
Dividend Yield | 0 | 0.08 | 0 | 0 | 0 | |
Payout ratio | 0 | -1.24 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.23 | -0.85 | -0.05 | -0.03 | -0.34 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.73 | 4.44 | 4.29 | 4.31 | 4.22 | |
ROIC | -0.14 | -0.13 | -0.11 | -0.09 | -0.12 | |
Return on tangible assets | -0.13 | -0.11 | -0.1 | -0.08 | -0.11 | |
Graham Net | 2.84 | 2.12 | 2.12 | 2.59 | 2.08 | |
Working capital | 116.68M | 121.57M | 131.51M | 188.58M | 181.56M | |
Tangible asset value | 118.39M | 103.35M | 105.59M | 160.21M | 140.48M | |
Net current asset value | 110.59M | 95.7M | 98.25M | 155.37M | 135.88M | |
Invested capital | 0.06 | 0.26 | 0.32 | 0.21 | 0.33 | |
Average receivables | 105.5K | 57.5K | 0 | 0 | 192.5K | |
Average payables | 1.97M | 2.18M | 1.91M | 2.01M | 1.59M | |
Average inventory | -57.5K | -57.5K | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 733.85 | 504.17 | 547.61 | 542.16 | 342.94 | |
Days of inventory on hand | -33.17 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.12 | 0.18 | 0.16 | 0.17 | 0.26 | |
Inventory turnover | -2.71 | 0 | 0 | 0 | 0 | |
ROE | -0.15 | -0.16 | -0.15 | -0.1 | -0.15 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
INZY Frequently Asked Questions
What is Inozyme Pharma, Inc. stock symbol ?
Inozyme Pharma, Inc. is a US stock , located in Boston of Ma and trading under the symbol INZY
What is Inozyme Pharma, Inc. stock quote today ?
Inozyme Pharma, Inc. stock price is $7.57 today.
Is Inozyme Pharma, Inc. stock public?
Yes, Inozyme Pharma, Inc. is a publicly traded company.